Narula, GBhagwat, RArora, BBanavali, SdPai, SkNair, CnSeth, TLaskar, SMuckaden, MaKurkure, PaParikh, Pm2009-05-282009-05-282007-07-06Narula G, Bhagwat R, Arora B, Banavali S, Pai S, Nair C, Seth T, Laskar S, Muckaden M, Kurkure P, Parikh P. Clinico-biologic profile of Langerhans cell histiocytosis: a single institutional study. Indian Journal of Cancer. 2007 Jul-Sep; 44(3): 93-8http://imsear.searo.who.int/handle/123456789/50721CONTEXT: Langerhans cell histiocytosis (LCH) is a rare atypical cellular disorder characterized by clonal proliferation of Langerhans cells leading to myriad clinical presentations and highly variable outcomes. There is a paucity of Indian studies on this subject. AIM: To present the experience of management of LCH at a single institution. SETTINGS AND DESIGN: This is a retrospective observational study of patients with LCH who presented at the Tata Memorial Hospital between January 1987 and December 2002. MATERIALS AND METHODS: Fifty-two patients with LCH were treated in the study period. Due to the long observation period and variability in diagnostic and therapeutic protocols, the patients were risk-stratified based on present criteria. The disease pattern, management approaches and treatment outcomes of patients were recorded. STATISTICAL ANALYSIS USED: Statistical analyses were done using Student's 't' test, test for proportion and survival estimates based on the Kaplan-Meier method. RESULTS: The median age at presentation was 3 years and more than 48% of the patients had Group I disease. Skeleton, skin and lymphoreticular system were the commonly involved organs. Majority (80%) required some form of therapy. The projected overall survival is 63% at 10 years and mean survival is 118 months. Seventeen percent of surviving patients developed long-term sequelae. CONCLUSIONS: The clinico-biologic profile of LCH patients in India is largely similar to international patterns except a higher incidence of lymphoreticular involvement. Majority of the patients respond favorably to therapy and have a good outcome, except a subset of Group I patients who warrant enrollment in clinical trials with innovative therapeutic strategies to improve outcome.engAdolescentAdultAntineoplastic Agents --therapeutic useChildChild, PreschoolFemaleHistiocytosis, Langerhans-Cell --diagnosisHumansInfantMaleMiddle AgedRadiotherapyRetrospective StudiesRisk FactorsTreatment OutcomeJournal Article